202 related articles for article (PubMed ID: 36356199)
21. Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes.
Li M; Liu X; Zhang S; Liang S; Zhang Q; Chen J
Phys Chem Chem Phys; 2022 Sep; 24(36):22129-22143. PubMed ID: 36082845
[TBL] [Abstract][Full Text] [Related]
22. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
[TBL] [Abstract][Full Text] [Related]
23. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.
Steuten K; Kim H; Widen JC; Babin BM; Onguka O; Lovell S; Bolgi O; Cerikan B; Neufeldt CJ; Cortese M; Muir RK; Bennett JM; Geiss-Friedlander R; Peters C; Bartenschlager R; Bogyo M
ACS Infect Dis; 2021 Jun; 7(6):1457-1468. PubMed ID: 33570381
[TBL] [Abstract][Full Text] [Related]
24. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
[TBL] [Abstract][Full Text] [Related]
25. Primer for Designing Main Protease (M
Thakur A; Sharma G; Badavath VN; Jayaprakash V; Merz KM; Blum G; Acevedo O
J Phys Chem Lett; 2022 Jun; 13(25):5776-5786. PubMed ID: 35726889
[TBL] [Abstract][Full Text] [Related]
26. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
[TBL] [Abstract][Full Text] [Related]
27. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
[TBL] [Abstract][Full Text] [Related]
28. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.
Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF
J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 M
Qiao J; Li YS; Zeng R; Liu FL; Luo RH; Huang C; Wang YF; Zhang J; Quan B; Shen C; Mao X; Liu X; Sun W; Yang W; Ni X; Wang K; Xu L; Duan ZL; Zou QC; Zhang HL; Qu W; Long YH; Li MH; Yang RC; Liu X; You J; Zhou Y; Yao R; Li WP; Liu JM; Chen P; Liu Y; Lin GF; Yang X; Zou J; Li L; Hu Y; Lu GW; Li WM; Wei YQ; Zheng YT; Lei J; Yang S
Science; 2021 Mar; 371(6536):1374-1378. PubMed ID: 33602867
[TBL] [Abstract][Full Text] [Related]
30. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
Deodato D; Asad N; Dore TM
Bioorg Med Chem Lett; 2022 Sep; 72():128867. PubMed ID: 35760254
[TBL] [Abstract][Full Text] [Related]
32. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M
Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D
Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708
[TBL] [Abstract][Full Text] [Related]
33. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
34. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance.
Shaqra AM; Zvornicanin SN; Huang QYJ; Lockbaum GJ; Knapp M; Tandeske L; Bakan DT; Flynn J; Bolon DNA; Moquin S; Dovala D; Kurt Yilmaz N; Schiffer CA
Nat Commun; 2022 Jun; 13(1):3556. PubMed ID: 35729165
[TBL] [Abstract][Full Text] [Related]
35. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577
[TBL] [Abstract][Full Text] [Related]
36. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
[TBL] [Abstract][Full Text] [Related]
37. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
La Monica G; Bono A; Lauria A; Martorana A
J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
[TBL] [Abstract][Full Text] [Related]
38. Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion.
Fuzo CA; Martins RB; Fraga-Silva TFC; Amstalden MK; Canassa De Leo T; Souza JP; Lima TM; Faccioli LH; Okamoto DN; Juliano MA; França SC; Juliano L; Bonato VLD; Arruda E; Dias-Baruffi M
Drug Dev Res; 2022 Nov; 83(7):1623-1640. PubMed ID: 35989498
[TBL] [Abstract][Full Text] [Related]
39. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
40. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
